A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system

Bispecific T-cell engagers (BiTEs) may break multiple barriers that currently limit the use of immunotherapy in glioblastoma patients. We have recently described a novel BiTE specific for a mutated form of the epidermal growth factor receptor, EGFRvIII, that exerts potent antineoplastic effects agai...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Bryan D., Pastan, Ira, Bigner, Darell D., Sampson, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654588/
https://www.ncbi.nlm.nih.gov/pubmed/23734318
http://dx.doi.org/10.4161/onci.23639
Descripción
Sumario:Bispecific T-cell engagers (BiTEs) may break multiple barriers that currently limit the use of immunotherapy in glioblastoma patients. We have recently described a novel BiTE specific for a mutated form of the epidermal growth factor receptor, EGFRvIII, that exerts potent antineoplastic effects against established invasive tumors of the brain.

Ejemplares similares